Immunophenotyping, clonality and molecular assay interpretation
Define the target and the purpose
An immunohistochemical antibody recognizes an antigen under the assay conditions; a nucleic-acid test detects a defined molecular target. Neither technique automatically identifies every possible disease process. Decide whether the question concerns cell lineage, an infectious agent, a mutation, clonality or another feature. A test useful for detection may not establish causation, prognosis or treatment response. The submitted sample must actually contain relevant lesional material for the question to be answerable.
Interpret panels with morphology
Cytokeratins support epithelial differentiation, and selected lymphoid markers contribute to B-cell or T-cell assessment. Some markers are expressed in more than one cell type or can be lost by a tumor. A panel can improve interpretation, but a list of positives is not a substitute for tissue architecture and suitable controls. Species validation, fixation, antigen retrieval and background staining affect performance. A negative result may reflect biology or a technical limitation rather than a definitive exclusion.
Understand what clonality does and does not mean
Lymphocytes rearrange antigen-receptor genes during development, allowing targeted assays to examine population patterns. A dominant reproducible pattern can support clonality in the appropriate context. Reactive expansion, limited templates, assay coverage and poor DNA quality can complicate interpretation. Clonal does not always mean malignant, and a polyclonal or nondiagnostic result does not automatically rule out lymphoma. Combine the result with histology, cytology, immunophenotype and clinical findings.
Preserve location and quantitative limits
In situ techniques retain target location within tissue, while extraction-based assays can detect material without showing which cells contain it. Quantitative PCR requires an appropriate validated model and controls; a cycle threshold is not a universal count of viable organisms across laboratories. A tumor-associated mutation can support classification or a therapeutic discussion without guaranteeing clinical response. Separate analytic detection from clinical interpretation and describe uncertainty explicitly. Current assays and evidence evolve, so do not transfer a branded test's performance or a numerical cutoff to every specimen, species and laboratory without validation.